Detected ·
Crystalys Therapeutics Inc.
$130M—
Crystalys Therapeutics Inc., a clinical-stage biopharmaceutical company focused on gout treatment, announced the closing of an oversubscribed $130M Series B financing to support late-stage global clinical development and commercialization of dotinurad, a next-generation oral URAT1 inhibitor.
- Website
- —
- —
- Amount
- $130 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-24 00:08:38 UTC
- Signal ID
- 3449739f-1cfc-463d-a735-007e7edf2d39
As the API returns it
{
"id": "3449739f-1cfc-463d-a735-007e7edf2d39",
"created_at": "2026-07-24T00:08:38.283211Z",
"company_name": "Crystalys Therapeutics Inc.",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 130000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Crystalys Therapeutics Inc., a clinical-stage biopharmaceutical company focused on gout treatment, announced the closing of an oversubscribed $130M Series B financing to support late-stage global clinical development and commercialization of dotinurad, a next-generation oral URAT1 inhibitor.*"
}